Protocol | Alliance A071601 |
---|---|
Cancer Type: | CRANIOPHARYNGIOMAS |
Fast Facts |
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A071702 |
---|---|
Cancer Type: | Recurrent Glioblastoma |
Fast Facts |
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG BN011 |
---|---|
Cancer Type: | Methylated MGMT Promoter Glioblastoma |
Fast Facts |
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | N0577 |
---|---|
Cancer Type: | Codeleted Anaplastic Glioma |
Fast Facts |
Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A071401 |
---|---|
Cancer Type: | MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS |
Fast Facts |
PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS
Protocol | NRG BN003 |
---|---|
Cancer Type: | MENINGIOMA |
Fast Facts |
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A071701 |
---|---|
Cancer Type: | Brain metastases |
Fast Facts |
Genomically-Guided Treatment Trial in Brain Metastases
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | WF 1801 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ACNS1422 |
---|---|
Cancer Type: | Medulloblastoma |
Fast Facts |
A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Age - Patients must be Greater than or Equal to 3 Years and Less than 22 Years of Age at the Time of Enrollment on ACNS1422 Step 0.
Protocol | COG ACNS1723 |
---|---|
Cancer Type: | High-Grade Glioma |
Fast Facts |
A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.
Note: The HGG Pre-Enrollment Eligibility Screening (Step 0) has been paused until further notice.
Protocol | COG ACNS1831 |
---|---|
Cancer Type: | Low-Grade Glioma |
Fast Facts |
A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.
Protocol | COG ACNS1833 |
---|---|
Cancer Type: | Low-Grade Glioma |
Fast Facts |
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.
Protocol | COG ANBL00B1 |
---|---|
Cancer Type: | Neuroblastoma-Biology |
Fast Facts |
Neuroblastoma Biology Studies
All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study.
Protocol | COG ACNS1931 |
---|---|
Cancer Type: | Low Grade Glioma |
Fast Facts |
COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.
Protocol | COG ACNS2021 |
---|---|
Cancer Type: | CNS - Germ Cell |
Fast Facts |
COG ACNS2021
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.
Protocol | COG ACNS1821 |
---|---|
Cancer Type: | CNS - DIPG & HGG |
Fast Facts |
COG ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Patients must be ≥ 12 months and ≤ 21 years of age at the time of enrollment.
Step 1 enrollment is temporarily closed to accrual.
Protocol | COG ACCL2031 |
---|---|
Cancer Type: | CNS |
Fast Facts |
COG ACCL2031
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Protocol | COG ACNS2031 |
---|---|
Cancer Type: | Medulloblastoma |
Fast Facts |
COG-ACNS2031: A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features
Age: ≥ 4 years and ≤ 21 years of age at the time of enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA1181 |
---|---|
Cancer Type: | Neoadjuvant Breast |
Fast Facts |
Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1706 |
---|---|
Cancer Type: | Inflammatory Breast Cancer |
Fast Facts |
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Protocol | Alliance A011801 |
---|---|
Cancer Type: | HER2 positive Breast Cancer |
Fast Facts |
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | CCTG MA.39 Adjuvant |
---|---|
Cancer Type: | LOW RISK NODE POSITIVE BREAST CANCER |
Fast Facts |
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Protocol | NRG BR007 |
---|---|
Cancer Type: | Stage 1, Hormone Sensitive Her2 negative |
Fast Facts |
Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S2007 |
---|---|
Cancer Type: | HER2-Negative Breast Cancer |
Fast Facts |
A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1501 CC cardiac tox |
---|---|
Cancer Type: | METASTATIC HER-2+ BREAST CANCER |
Fast Facts |
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
Protocol | SWOG S1703 |
---|---|
Cancer Type: | METASTATIC BREAST CANCER |
Fast Facts |
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Protocol | URCC 16070 CC nausea |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Treatment of Refractory Nausea
Protocol | Alliance A231901CD |
---|---|
Cancer Type: | CCDR |
Fast Facts |
IMPROVING PATIENT-CENTERED COMMUNICATION IN BREAST CANCER: A RCT OF A SHARED DECISION ENGAGEMENT SYSTEM (SHARES)
Protocol | Alliance A191901 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Protocol | SWOG S2010 |
---|---|
Cancer Type: | Breast |
Fast Facts |
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A211801 |
---|---|
Cancer Type: | BRCA Breast |
Fast Facts |
A211801 - BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation
Protocol | EA1151 (TMIST) |
---|---|
Cancer Type: | Screening |
Fast Facts |
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A231901CD |
---|---|
Cancer Type: | CCDR |
Fast Facts |
IMPROVING PATIENT-CENTERED COMMUNICATION IN BREAST CANCER: A RCT OF A SHARED DECISION ENGAGEMENT SYSTEM (SHARES)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1912CD |
---|---|
Cancer Type: | CCDR |
Fast Facts |
A RANDOMIZED TRIAL ADDRESSING CANCER-RELATED FINANCIAL HARDSHIP THROUGH
DELIVERY OF A PROACTIVE FINANCIAL NAVIGATION INTERVENTION (CREDIT)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ACCL20N1CD |
---|---|
Cancer Type: | ALL |
Fast Facts |
COG ACCL20N1CD: Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A212102 |
---|---|
Cancer Type: | Early Detection Blood Tests |
Fast Facts |
Blinded Reference Set for Multicancer Early Detection Blood Tests
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | WF 1801 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1501 CC cardiac tox |
---|---|
Cancer Type: | METASTATIC HER-2+ BREAST CANCER |
Fast Facts |
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
Protocol | SWOG S1703 |
---|---|
Cancer Type: | METASTATIC BREAST CANCER |
Fast Facts |
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Protocol | URCC 16070 CC nausea |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Treatment of Refractory Nausea
Protocol | SWOG S1904 |
---|---|
Cancer Type: | ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU |
Fast Facts |
CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH
ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)
Protocol | Alliance A191901 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | WF 1806 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
Protocol | Alliance A221805 |
---|---|
Cancer Type: | CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY |
DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAQ172 |
---|---|
Cancer Type: | Pneumonitis |
Fast Facts |
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A211901 |
---|---|
Cancer Type: | Rural Cancer Survivors |
Fast Facts |
REACHING RURAL CANCER SURVIVORS WHO SMOKE USING TEXT-BASED CESSATION INTERVENTIONS
Protocol | URCC 21038 |
---|---|
Cancer Type: | Cancer Survivors |
Fast Facts |
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
Protocol | URCC 19185 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
Protocol | SWOG S2205 |
---|---|
Cancer Type: | peripheral neuropathy |
Fast Facts |
S2205, ICE COMPRESS: RANDOMIZED TRIAL OF LIMB CRYOCOMPRESSION VERSUS CONTINUOUS COMPRESSION VERSUS LOW CYCLIC COMPRESSION FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY
Protocol | URCC 18007 |
---|---|
Cancer Type: | Cancer-Related Fatigue |
Fast Facts |
Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA1151 (TMIST) |
---|---|
Cancer Type: | Screening |
Fast Facts |
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Protocol | EA2185 |
---|---|
Cancer Type: | Pancreatic Cyst Surveillance |
Fast Facts |
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Protocol | DCP-001 |
---|---|
Cancer Type: | Multisite - Screening |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Protocol | NRG CC005 FORTE |
---|---|
Cancer Type: | Colonoscopy |
Fast Facts |
FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ALTE03N1 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
Key Adverse Events After Childhood Cancer
Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.
Protocol | COG ALTE07C1 |
---|---|
Cancer Type: | Multi-Site Cancer Control |
Fast Facts |
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A021804 |
---|---|
Cancer Type: | ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA |
A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG GI005 |
---|---|
Cancer Type: | Stage IIA Colon Cancer |
Fast Facts |
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Protocol | NRG GI008 |
---|---|
Cancer Type: | Colon Adjuvant |
Fast Facts |
COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2186 |
---|---|
Cancer Type: | Metastatic Pancreatic |
Fast Facts |
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Protocol | SWOG S2001 |
---|---|
Cancer Type: | Metastatic Pancreatic |
Fast Facts |
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.
Protocol | Alliance A021806 |
---|---|
Cancer Type: | RESECTABLE PANCREATIC CANCER |
Fast Facts |
A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1922 |
---|---|
Cancer Type: | Small bowel Adenocarcinoma |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2176 |
---|---|
Cancer Type: | treatment-naïve metastatic anal cancer |
Fast Facts |
A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients
Protocol | EA2182 |
---|---|
Cancer Type: | Early Stage Anal Squamous Cell Carcinoma |
Fast Facts |
A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2197 |
---|---|
Cancer Type: | Incidental Gallbladder Cancer |
Fast Facts |
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG GI004 |
---|---|
Cancer Type: | Colorectal Cancer |
Fast Facts |
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Protocol | SWOG S2107 |
---|---|
Cancer Type: | Metastatic Colorectal |
Fast Facts |
Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2183 |
---|---|
Cancer Type: | Esophageal and Gastric Adenocarcinoma |
Fast Facts |
A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | WF 1806 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
Protocol | Alliance A221805 |
---|---|
Cancer Type: | CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY |
DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA2185 |
---|---|
Cancer Type: | Pancreatic Cyst Surveillance |
Fast Facts |
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AHEP1531 |
---|---|
Cancer Type: | PHITT |
Fast Facts |
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Age: Patients must be ≤ 30 Years of Age at the Time of Diagnosis
As of June 30, 2022, AHEP1531 Group D is temporarily closed to accrual.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1802 |
---|---|
Cancer Type: | Metastatic Prostate Cancer |
Fast Facts |
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Protocol | EA8171 |
---|---|
Cancer Type: | Prostate Cancer |
Fast Facts |
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
Protocol | NRG GU009 |
---|---|
Cancer Type: | HIGH RISK PROSTATE CANCER |
Fast Facts |
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
Protocol | Alliance A031902 |
---|---|
Cancer Type: | Prostate Cancer |
Fast Facts |
A PHASE III TRIAL OF ENZALUTAMIDE AND RUCAPARIB AS A NOVEL THERAPY IN FIRST-LINE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Protocol | NRG GU010 |
---|---|
Cancer Type: | Prostate Cancer |
Fast Facts |
NRG-GU010 - Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A031704 |
---|---|
Cancer Type: | METASTATIC UNTREATED RENAL CELL |
Fast Facts |
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell Cancer [PDIGREE] |
Protocol | SWOG S1931 |
---|---|
Cancer Type: | METASTATIC RENAL CELL CARCINOMA |
Fast Facts |
PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)
Protocol | SWOG S2200 |
---|---|
Cancer Type: | Renal Cell |
Fast Facts |
SWOG - S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).”
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A031803 |
---|---|
Cancer Type: | BCG-Unresponsive Non Muscle Invasive Bladder |
Fast Facts |
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Protocol | SWOG S1806 |
---|---|
Cancer Type: | Bladder Cancer |
Fast Facts |
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer
Protocol | SWOG S1937 |
---|---|
Cancer Type: | Metastatic Urothelial Carcinoma |
Fast Facts |
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Protocol | Alliance A032001 |
---|---|
Cancer Type: | METASTATIC UROTHELIAL CANCER |
Fast Facts |
MAIN-CAV: PHASE III RANDOMIZED TRIAL OF MAINTENANCE CABOZANTINIB AND AVELUMAB VS MAINTENANCE AVELUMAB AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH METASTATIC UROTHELIAL CANCER
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A031702 |
---|---|
Cancer Type: | rare genitourinary tumors |
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1823 |
---|---|
Cancer Type: | Newly Diagnosed Germ Cell Tumors |
Fast Facts |
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AREN03B2 |
---|---|
Cancer Type: | Renal-Biology |
Fast Facts |
Renal Tumors Classification, Biology, and Banking Study
Patients must be < 30 Years Old at the Time of Diagnosis
Protocol | COG AREN1921 |
---|---|
Cancer Type: | Wilms |
Fast Facts |
COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Patients must be ≤ 30 years old at study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1823 |
---|---|
Cancer Type: | Newly Diagnosed Germ Cell Tumors |
Fast Facts |
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AGCT1531 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Age:
Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.
Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.
Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment.
Protocol | COG AGCT1532 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
Phase III Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Age ≥ 11 Years and ≤ 45 Years on the Date of Randomization
Protocol | COG ACNS2021 |
---|---|
Cancer Type: | CNS - Germ Cell |
Fast Facts |
COG ACNS2021
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG CC008 |
---|---|
Cancer Type: | Ovarian Cancer Among BRCA1 Carriers |
Fast Facts |
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Protocol | NRG GY019 |
---|---|
Cancer Type: | Carcinoma of the Ovary or Peritoneum |
Fast Facts |
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG GY026 |
---|---|
Cancer Type: | Endometrial serous carcinoma or carcinosarcoma |
Fast Facts |
A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma
Protocol | Alliance A092104 |
---|---|
Cancer Type: | ADVANCED UTERINE LEIOMYOSARCOMA |
Fast Facts |
A RANDOMIZED PHASE 2/3 STUDY OF OLAPARIB PLUS TEMOZOLOMIDE VERSUS INVESTIGATOR’S CHOICE FOR THE TREATMENT OF PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA AFTER PROGRESSION ON PRIOR CHEMOTHERAPY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG GY024 |
---|---|
Cancer Type: | Vulvar Cancer |
Fast Facts |
Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III), a prospective phase II treatment trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA3132 |
---|---|
Cancer Type: | Head and Neck |
Fast Facts |
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Protocol | EA3161 |
---|---|
Cancer Type: | HPV Positive OPCA |
Fast Facts |
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Protocol | NRG HN005 |
---|---|
Cancer Type: | Oropharyngeal Cancer |
Fast Facts |
A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Protocol | RTOG 1216 |
---|---|
Cancer Type: | Pathologic High-Risk Squamous Cell Cancer |
Fast Facts |
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A041501 |
---|---|
Cancer Type: | NEWLY DIAGNOSED PRECURSOR B-CELL ALL |
Fast Facts |
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ASCT2031 |
---|---|
Cancer Type: | leukemia |
Fast Facts |
COG-ASCT2031: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
Age: 6 months to <22 years at enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ACCL1931 |
---|---|
Cancer Type: | ALL |
Fast Facts |
COG-ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Age: ≥15 and <40 years at time of diagnosis.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A041701 |
---|---|
Cancer Type: | ACUTE MYELOID LEUKEMIA |
Fast Facts |
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1925 |
---|---|
Cancer Type: | CLL/SLL |
Fast Facts |
RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NHLBI-MDS |
---|---|
Cancer Type: | Myelodysplastic Syndromes |
Fast Facts |
The National Myelodysplastic Syndromes (MDS) Study
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AALL15P1 |
---|---|
Cancer Type: | Acute Lymphoblastic Leukemia (ALL) |
Fast Facts |
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
Infants Less than 1 Year of Age on the Date of Diagnosis are Eligible; Infants must be >36 Weeks Gestational Age at the Time of Enrollment.
Protocol | COG ACCL20N1CD |
---|---|
Cancer Type: | ALL |
Fast Facts |
COG ACCL20N1CD: Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
Protocol | COG AALL1621 |
---|---|
Cancer Type: | Relapsed Refractory CD22 B-ALL |
Fast Facts |
A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.
AALL1621 has been temporarily closed to accrual as of September 18, 2023, pending an evaluation of patients currently enrolled on this study.
Protocol | COG AALL1631 |
---|---|
Cancer Type: | Ph+ ALL |
Fast Facts |
International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Age: > 1 Year and < 21 Years at ALL Diagnosis
Protocol | COG AALL1731 |
---|---|
Cancer Type: | B-ALL, B-LLy |
Fast Facts |
A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)
Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)
Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS
Temporary Closure to Accrual as of 12/19/2022
Protocol | COG AALL1732 |
---|---|
Cancer Type: | B-ALL, B-LLy |
Fast Facts |
A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Patients must be > 365 Days and < 25 Years of Age
Protocol | COG AALL1821 |
---|---|
Cancer Type: | B-ALL |
Fast Facts |
COG AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Temporary Closure to Accrual as of 12/19/2022
Protocol | COG AAML18P1 |
---|---|
Cancer Type: | Chronic Myeloid Leukemia |
Fast Facts |
COG AAML18P1
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Patient must have been diagnosed with CML-CP at less than 18 years of age
Patient mustbe less than 25 years of age at enrollment
Protocol | COG AAML1831 |
---|---|
Cancer Type: | de nova AML |
Fast Facts |
COG-AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
Patients must be less than 22 years of age at the time of study enrollment.
Protocol | COG APAL2020SC |
---|---|
Cancer Type: | Relapsed Leukemia |
Fast Facts |
COG APAL2020SC
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Patients must be less than 22 years of age at the time of study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ECOG E4512 |
---|---|
Cancer Type: | Non-Small Cell Lung |
Fast Facts |
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A substudy of ALCHEMIST A151216
Protocol | EA5162 |
---|---|
Cancer Type: | Advanced NSCLC |
Fast Facts |
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
Protocol | EA5163 |
---|---|
Cancer Type: | Non-Small Cell Lung Cancer (NSCLC) |
Fast Facts |
A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
Protocol | EA5181 |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Protocol | NRG LU002 |
---|---|
Cancer Type: | METASTATIC NON-SMALL CELL LUNG CANCER |
Fast Facts |
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Protocol | SWOG S1914 |
---|---|
Cancer Type: | Early Stage NSCLC |
Fast Facts |
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Protocol | Alliance A081801 |
---|---|
Cancer Type: | resected NSCLC |
Fast Facts |
Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
Protocol | EA5191 |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
Protocol | SWOG S1900E |
---|---|
Cancer Type: | NS NSCLC |
Fast Facts |
A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study
Protocol | SWOG S2302 |
---|---|
Cancer Type: | Lung |
Fast Facts |
Non-Chemotherapy Treatment (ramucirumab plus pembrolizumab) or Usual Care forAdvanced Non-Small Cell Lung Cancer Following Immunotherapy
Protocol | Alliance A082002 |
---|---|
Cancer Type: | Non-Small Cell Lung Cancer |
Fast Facts |
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1827 |
---|---|
Cancer Type: | Small Cell Lung |
Fast Facts |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Protocol | NRG LU007 |
---|---|
Cancer Type: | ES-SCLC |
Fast Facts |
RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | PDM 9846 |
---|---|
Cancer Type: | Tissue Procurement |
Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A151216 |
---|---|
Cancer Type: | Non-Small Cell Lung |
Fast Facts |
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Sub-Studies to ALCHEMIST: E4512 and EA5142
Protocol | LUNG MAP |
---|---|
Cancer Type: | NSCLC |
Fast Facts |
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A051701 |
---|---|
Cancer Type: | Double-hit and double-expressing lymphomas |
Fast Facts |
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas |
Protocol | SWOG S2114 |
---|---|
Cancer Type: | Lymphoma |
Fast Facts |
A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1608 |
---|---|
Cancer Type: | FOLLICULAR LYMPHOMA |
Fast Facts |
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1925 |
---|---|
Cancer Type: | CLL/SLL |
Fast Facts |
RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AHOD2131 |
---|---|
Cancer Type: | Classic Hodgkin Lymphoma |
Fast Facts |
COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Patients must be 5 to 60 years of age at the time of enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ANHL1931 |
---|---|
Cancer Type: | Lymphoma |
Fast Facts |
COG ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
This is an AYA protocol ≥ 2 years
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | URCC 18007 |
---|---|
Cancer Type: | Cancer-Related Fatigue |
Fast Facts |
Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | TAPUR |
---|---|
Cancer Type: | Multisite |
Fast Facts |
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Protocol | SWOG S2101 |
---|---|
Cancer Type: | melanoma |
Fast Facts |
S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | 10323 Moonshot |
---|---|
Cancer Type: | Biospecimen |
Fast Facts |
Cancer Moonshot Biobank Research Protocol
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | DCP-001 |
---|---|
Cancer Type: | Multisite - Screening |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AGCT1531 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Age:
Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.
Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.
Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment.
Protocol | COG APEC14B1 |
---|---|
Cancer Type: | All patients |
Fast Facts |
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.
Protocol | COG ALTE03N1 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
Key Adverse Events After Childhood Cancer
Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.
Protocol | COG ALTE05N1 |
---|---|
Cancer Type: | Multisite Long Term Follow-up |
Fast Facts |
Umbrella Long-Term Follow-Up Protocol
Only Available to Patients Already Enrolled on a COG Intervention Protocol.
Protocol | COG ALTE07C1 |
---|---|
Cancer Type: | Multi-Site Cancer Control |
Fast Facts |
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Protocol | COG APEC1621 – MATCH Protocol SC |
---|---|
Cancer Type: | Screening |
Fast Facts |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Protocol | COG APEC1621 - MATCH |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol
Protocol | COG APEC1621 - MATCH Protocol A |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol F |
---|---|
Cancer Type: | Molecular |
COG APEC1621F
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol K |
---|---|
Cancer Type: | Molecular |
APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol M |
---|---|
Cancer Type: | Molecular |
APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations
Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol N |
---|---|
Cancer Type: | Molecular |
APEC1621N: NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG ARST1921 |
---|---|
Cancer Type: | Other |
Fast Facts |
COG-ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Temporary Closure to Accrual as of 12/12/2022
Protocol | COG ANHL2121 |
---|---|
Cancer Type: | LCH |
Fast Facts |
COG-ANHL2121: Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Age: 180 days- <22 years (at time of study enrollment).
Protocol | COG ACCL21C2 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
COG-ACCL21C2: Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
≥6 months and ≤37 years of age at time of enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAA181 |
---|---|
Cancer Type: | Newly diagnosed Multiple Myeloma |
Fast Facts |
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAA173 |
---|---|
Cancer Type: | Smoldering Myeloma |
Fast Facts |
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1803 |
---|---|
Cancer Type: | Multiple Myeloma |
Fast Facts |
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ANBL00B1 |
---|---|
Cancer Type: | Neuroblastoma-Biology |
Fast Facts |
Neuroblastoma Biology Studies
All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study.
Protocol | COG ANBL1531 |
---|---|
Cancer Type: | High-Risk Neuroblastoma |
Fast Facts |
A Phase III Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Age - Patient must be ≥ 365 Days and ≤ 30 Years of Age at Diagnosis.
ARM C perm closed
Protocol | COG ANBL1821 |
---|---|
Cancer Type: | Neuroblastoma |
Fast Facts |
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Patients ≥ 1 year of age at the time of enrollment are eligible for this study.
Temporary Closed to Accrual as of March 06, 2023
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A021804 |
---|---|
Cancer Type: | ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA |
A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Protocol | SWOG S2012 |
---|---|
Cancer Type: | RARE |
RANDOMIZED PHASE II/III TRIAL OF FIRST LINE PLATINUM/ETOPOSIDE WITH OR WITHOUT
ATEZOLIZUMAB (NSC#783608) IN PATIENTS WITH POORLY DIFFERENTIATED
EXTRAPULMONARY SMALL CELL NEUROENDOCRINE CARCINOMAS (NEC)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1922 |
---|---|
Cancer Type: | Small bowel Adenocarcinoma |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A031702 |
---|---|
Cancer Type: | rare genitourinary tumors |
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG HN010 |
---|---|
Cancer Type: | RARE |
A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A092001 |
---|---|
Cancer Type: | RARE |
PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AOST2032 |
---|---|
Cancer Type: | Osteosarcoma |
Fast Facts |
COG-AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Patients must be < 40 years of age at the time of enrollment.
Protocol | COG ARST2032 |
---|---|
Cancer Type: | Rhabdomyosarcoma |
Fast Facts |
COG- ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Patients must be ≤ 21 years at the time of enrollment.
Protocol | COG AOST2031 |
---|---|
Cancer Type: | Osteosarcoma |
Fast Facts |
COG AOST2031
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Patients must be < 50 years at the time of enrollment
Protocol | COG-ARST2031 |
---|---|
Cancer Type: | High Risk Rhabdomyosarcoma (HR-RMS) |
Fast Facts |
COG ARST2031
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Patients must be ≤ 50 years of age at the time of enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ECOG EA6141 |
---|---|
Cancer Type: | Melanoma-unresectable |
Fast Facts |
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Protocol | EA6192 |
---|---|
Cancer Type: | Advanced Melanoma |
Fast Facts |
A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Protocol | SWOG S2000 |
---|---|
Cancer Type: | Melanoma with Brain Metastases |
Fast Facts |
A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Symptomatic Brain Metastases
Protocol | EA6194 |
---|---|
Cancer Type: | Operable Melanoma |
Fast Facts |
Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
Protocol | SWOG S2015 |
---|---|
Cancer Type: | primary cutaneous melanoma |
Fast Facts |
Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
Protocol | Alliance A091903 |
---|---|
Cancer Type: | RESECTED MUCOSAL MELANOMA |
Fast Facts |
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EA6174 |
---|---|
Cancer Type: | Merkel Cell Carcinoma |
Fast Facts |
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.